October 1st 2025, 1:00pm
Dr. Mary B. Beasley discusses evolving role of pathologists in lung cancer care, highlighting how emerging technologies may shape the future of the field.
September 30th 2025, 9:00pm
Heather Ann Yonker expands on strategies for maintaining food safety in the home, particularly for patients with compromised immune systems due to cancer.
September 30th 2025, 8:00pm
Frank Garred, 77, completed Inlexzo treatment for recurrent bladder cancer, describing it as manageable with minimal side effects compared with BCG.
September 30th 2025, 1:00pm
Dr. Edgardo Santos explains that combining Tagrisso with chemotherapy or Leclaza plus Rybrevant may improve survival versus monotherapy alone.
September 29th 2025, 4:00pm
Dr. Sandip Patel discusses findings from a real-world study of biomarker testing in early-stage resected non-small cell lung cancer in the U.S.
September 29th 2025, 1:00pm
Dr. Patrick J. Hensley shares the treatment landscape of non-muscle-invasive bladder, as well as how individual risk factors can alter treatment options.
September 28th 2025, 6:00pm
Dr. Patrick Wen discussed with CURE how Modeyso treats diffuse midline glioma, and what unmet needs remain for patients now that the therapy is available.
September 26th 2025, 8:00pm
Ibtrozi may become the new standard for ROS1-mutated lung cancer, with phase 2 data showing safer, longer-lasting benefits for patients.
September 25th 2025, 9:00pm
Targeted therapies have changed non-small cell lung cancer care, but new side effects, like weight gain, are emerging, says Dr. Lorenzo Belluomini.
September 25th 2025, 8:00pm
Dr. Jacob A. Sands shares how patients with lung cancer can interpret clinical trial results and how these findings translate to treatment decisions.
Understanding Your Diagnosis of Bile Duct Cancer
Understanding Your Stage 2 Uterine (Endometrial) Cancer
Top Blood Cancer Stories from October: Key Updates for Patients
Expert Explains Need for Better Outcomes in Resectable Lung Cancer